



IOL Chemicals and Pharmaceuticals Limited

Investor Presentation

August 2021

This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expressed herein. Investors/shareholders/public are hence cautioned not to place undue reliance on these statements/details, and are advised to conduct their own investigation and analysis of the information contained or referred to in this section before taking any action with regard to their own specific objectives. Further, the discussion following here in reflects the perceptions on major issues as on date and the opinions expressed here are subject to change without notice. The Company under takes no obligation to publicly update or revise any of the opinions or forward-looking statements expressed in this section, consequent to new information, future events or otherwise.



Incorporated in 1986, IOLCP is one of the leading Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities



Catering to the top-tier players across diverse important industries like pharmaceuticals, ink industry, flexible packaging, adhesives, surface coatings, flavours, paints & lamination and essences etc.



Captive co-generation unit with capacity of 17 MW to meet power and steam requirements



To be amongst the most admired companies in APIs, Intermediates and Specialty Chemicals globally.



To provide top quality products in APIs, Intermediates and Specialty Chemicals through continuous innovation and cutting-edge technology with due regards to safety and environment.

Values

We, at IOLCP, believe values bring character to any organization that help leaders to guide teams for a culture of excellence through continuous improvements.



Team size of 2,000+ employees



Largest producer of Ibuprofen and the only company worldwide being backward integrated with ~35% Global share



Largest producer of Ethyl Acetate at Single Location in India




2nd Largest producer of Iso Butyl Benzene (IBB) with ~30% Global share



Over 20 products are commercialised with 8 products in pipeline



Debt free company, No debt raised since 2017



Spread over a sprawling campus of over 100 acres



Zero Discharge Effluent Treatment Plant



Customer base across 80 countries



Credit Rating: A+, outlook; stable (Care Ratings Limited)



Varinder Gupta
(Managing Director)

Mr. Varinder is an industrialist and has wide and rich experience of more than 35 years in the chemical & fertilizer industry and along with a comprehensive approach and strong Pharma API industry oversight has paved a way for innovation and excellence.



Vikas Gupta
(Executive Director)

Mr. Vikas is academically equipped with the knowledge and possesses organizational capacity. He has worked in strategic department of the company and played a main role in guiding the Chemical and Pharmaceutical business of the company. He has been vital to the functioning of the company over the last 7 years.



Dr. Sanjay Chaturvedi
(Chief Executive Officer)

Dr. Sanjay is a seasoned global business executive having worked in the specialty chemicals and pharmaceutical industry for over 25 years in companies like Praj Industries, Dr. Reddy's, Aurobindo among few others. He brings a demonstrated track record along with functional expertise in Sales, Marketing, Strategy, Manufacturing and R&D in USA and in India.



Kushal Kumar Rana
(Director - Works)

Mr. Kushal comes from a strong technical background having done his Bachelor's in Chemistry, Physics, Math and Master's degree in Chemistry. He has a rich experience of over 30 years in the pharmaceutical industry in companies like Morepen Laboratories, Chemiplast Industries His expertise lies in looking after quality assurance, quality control & corporate regulatory affairs.



Rajender Mohan Malla
(Chairman and Independent Director)

- Mr. Rajender has very distinguished career of four decades.
- He had held top and significant decision-making positions in Banks, Financial Institutions & NBFCs.
- In his most recent executive roles, he was MD & CEO of PTC India Financial Services Limited (PFS), and prior to that CMD of IDBI.




Dr. Sandhya Mehta
(Independent Director)

- Dr. Sandhya is working as the principal of Guru Nanak Institute of Management & technology, Ludhiana and has vast 22 year experience to her credit.
- She has published seven books in addition to numerous papers published in reputed National & international Journals.



Harpal Singh
(Independent Director)

- Mr. Harpal has had over 35 year's experience of banking and financial services.
- Most recently he was General Manager of Punjab National Bank and headed entire operations of bank in State of Punjab from 2010 to 2015.



*Unit-10 was commercialized in Q1FY22

Certifications and Accreditations



Approved USFDA Ibuprofen facility since 2015, recertified in 2019



EUGMP Certification in 2013, 2017 & Recertification in 2020



Certificate of Suitability from EDQM for IBUPROFEN, CEP No. 316-2008



Certificate of Suitability from EDQM for LAMOTRIGINE, CEP No. 066-2013



EDMF submitted to EDQM for Clopidogrel Hydrogen Sulfate



Certificate of Suitability from EDQM for METFORMIN, CEP No. 188-2013



ISO 9001:2015, 14001:2015 & 45001:2018



Certificate of Suitability from EDQM for Clopidogrel, CEP No. 006-2019



WHOGMP (COPP) for Ibuprofen, Metformin, Lamotrigine, Fenofibrate & Clopidogrel, UDCA & Pantoprazole Sodium



Written confirmation from CDSCO for Ibuprofen, Metformin, Lamotrigine, Fenofibrate Clopidogrel



Certificate of Suitability from EDQM for FENOFIBRATE CEP No. 075 2018



*Product
Segmentation*





IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen



Among the largest producer of Metformin in world



Added more than 7 new products in its API portfolio basket in last two years



Product portfolio that caters to over 7 therapeutic category

Product application across various therapeutic areas



Pain Management



Anti - Diabetic



Anti - Platelet



Anti - Cholesterol



Anti - Convulsant



Anti - Cholelithic



Proton Pump Inhibitor

API - Commercialized

Ibuprofen

Ibuprofen Lysinate

Ibuprofen Sodium

Dex-Ibuprofen

Metformin HCL

Clopidogrel Bisulphate (Form II)

Pantoprazole Sodium

Fenofibrate (Micronised)

Gabapentin

Lamotrigine

Ursodeoxycholic Acid

Losartan Potassium

Levetiracetam

API - Pipeline

Fexofenadine

Quetiapine Fumarate

Dextromethorphan

Apixaban



Mesalazine

Nebivolol



Lisinopril

Valsartan



Q1 FY22



Q4 FY21



Q1 FY21





▶ API manufactured in batch manner and intermediates & Specialty chemicals in continuous product delivery manner based on DCS technology

▶ Dedicated blocks involved in manufacturing of APIs

▶ Facility is coupled with ISO class-8 HVAC system, PSA Nitrogen & Purified water along with 127 MTPH steam generation capacity with multiple boilers

▶ Manufacturing facilities involves - Reactions, Filtration, Centrifugation, Drying, Blending & Sieving, Micronization operation


▶ Four stage treatment zero discharge ETP, solvent recovery plants & EHS cell as a part of the facility

▶ Dedicated decentralized utilities from -20 to 275 deg.C temp and dedicated co-generation plant of 17MW

Research & Development



R&D facility is in action 24*7



Working on generic molecules with latest equipment & techniques for process development



DSIR approved facility for research & development



In-house development of multi step products



- Strive to minimize the adverse impact on environment, health and Safety by upgrading technology, optimum utilization of resources and minimizing effluent / waste generation.
- Complying with the applicable statutory and legal requirements and providing safe working environment / work place by imparting training to all employees.
- Spread awareness about the EMS and Process Safety and necessary PPE.

Environment



- Construction and renovation of school locations, provided technical equipment for smart education
- Primary healthcare including sanitation
- Disaster relief by eradicating hunger, poverty and malnutrition
- Community development by setting up old age homes and community mentally retarded home
- Protection of art and culture
- Plantation in villages for restoration to environment
- Trust/Contribution

Corporate Social Responsibility

Solar Lights donated by IOLCP



Plantation activity conducted by IOLCP in Barnala



Financial Overview



Financial Summary


(INR Cr)

	Q1FY22	Q4FY21	Q1FY21
Total Income	524	467	466
Gross Profit	189	189	218
EBITDA	116	117	158
PAT	67	75	128


5 years Financial Performance - Annually




Revenues & Margins* - Annual




Margin* Expansion - Over the Years



Segmental EBIT %




Debt/Equity




*All Profits and Total Income include Other Income

Revenues & Margins*



Segmental EBIT %



*All Profits and Total Income include Other Income; PAT for Q1FY22 includes Exceptional Items

Geographical Segmental Breakup - Annual & Quarterly



In INR crs



*FY21 Covid Impact

Financial Summary - Balance Sheet



Balance Sheet (INR Crs)	FY17	FY18	FY19	FY20	FY21
Shareholder's Funds	188.7	215.7	474.3	813.5	1260.4
Debt	446.5	421.9	284.0	56.0	0.0
Other Long Term Liabilities	17.2	33.6	20.8	79.7	59.1
Other Current Liabilities	165.1	180.9	162.8	220.6	290.6
Equity & Liabilities	817.5	852.1	941.9	1169.8	1610.1
Fixed Assets	395.1	412.6	438.7	488.2	560.6
Other Non Current Assets	8.8	14.8	15.1	10.7	27.2
Non Current Assets	403.9	427.4	453.8	498.9	587.8
Investments	0.1	0.1	0.1	0.1	1.2
Cash & Bank Balances	16.8	17.3	29.6	154.7	364.7
Other Current Assets	396.7	407.3	458.4	516.1	656.4
Current Assets	413.6	424.7	488.1	670.9	1022.3
Assets	817.5	852.1	941.9	1169.8	1610.1

Financial Summary - Statement of Profit and Loss




P&L (INR Crs)	FY17	FY18	FY19	FY20	FY21	Q1FY22	Q4FY21	Q1FY21
Revenues	710.6	983.3	1,685.3	1,894.5	1,967.0	518.5	460.4	460.1
Other Income	1.3	6.3	10.4	16.0	24.3	5.7	6.2	5.8
Total Income	711.9	989.6	1,695.7	1,910.5	1,991.3	524.2	466.6	465.9
Gross Profits	234.5	294.4	648.5	845.5	888.4	189.2	188.9	217.7
<i>Gross Profits %*</i>	32.9%	29.7%	38.2%	44.3%	44.6%	36.1%	40.5%	46.7%
EBITDA	103.4	125.9	420.0	589.9	616.1	115.9	117.4	157.9
<i>EBITDA %*</i>	14.5%	12.7%	24.8%	30.9%	30.9%	22.1%	25.2%	33.9%
Depreciation	29.8	30.2	32.5	35.7	38.9	10.3	10.0	9.4
EBIT	73.6	95.7	387.6	554.2	577.2	105.6	107.4	148.5
<i>EBIT %*</i>	10.3%	9.7%	22.9%	29.0%	29.0%	20.1%	23.0%	31.9%
Interest	67.7	64.4	51.4	20.9	5.8	1.8	1.4	1.8
Earnings before exceptional items and taxes	5.9	31.3	336.2	533.3	571.4	103.8	106.0	146.7
Exceptional Items	-	-	-	-	-	13.9	-	-
Taxes	1.2	3.6	99.5	172.0	126.8	22.9	30.7	19.2
PAT	4.7	27.7	236.7	361.3	444.6	67.0	75.3	127.5
<i>PAT %*</i>	0.7%	2.8%	14.0%	18.9%	22.3%	12.8%	16.1%	27.4%


Stock Data (As on 30th June, 2021)

\$	Market Capitalization (₹)	3,569Cr₹
🌱	Face Value(₹)	10
📈	Share Price (₹)	608.1
💰	EPS (₹)	11.4
↑	52-Week High (₹)	898.4
↓	52-Week Low (₹)	516.3
🔍	Symbol(NSE/BSE)	IOLCP 524164

Shareholding Pattern (%)



IOLCP 5 Years Stock Price vs Sensex





Thank You

For further details:

Mr. Pardeep Kumar Khanna , CFO

Email: pardeepkhanna@iolcp.com

Phone: +91-161-2225531-35